398 related articles for article (PubMed ID: 28381462)
21. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
Wynja E; Solomon B; Bleeker J
J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
[TBL] [Abstract][Full Text] [Related]
22. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy in renal cell carcinoma.
Gul A; Rini BI
Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
[TBL] [Abstract][Full Text] [Related]
24. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
[TBL] [Abstract][Full Text] [Related]
25. Immune Checkpoint Therapy in Renal Cell Carcinoma.
Lee CH; Motzer RJ
Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
[TBL] [Abstract][Full Text] [Related]
26. RCDB: Renal Cancer Gene Database.
Ramana J
BMC Res Notes; 2012 May; 5():246. PubMed ID: 22608002
[TBL] [Abstract][Full Text] [Related]
27. Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is a Neoplastic Process: Clinicopathologic and Molecular Study of 7 Cases.
Agaimy A; Bonert M; Naqvi A; Wang C; Trpkov K; Dettmar P; Wintzer HO; Stoehr R; Hes O; Williamson SR; Gibson IW; Hartmann A
Am J Surg Pathol; 2020 Dec; 44(12):1658-1665. PubMed ID: 32910018
[TBL] [Abstract][Full Text] [Related]
28. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy.
Norian LA; Kresowik TP; Rosevear HM; James BR; Rosean TR; Lightfoot AJ; Kucaba TA; Schwarz C; Weydert CJ; Henry MD; Griffith TS
PLoS One; 2012; 7(2):e31085. PubMed ID: 22312440
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in immunotherapy for kidney cancer.
Ball MW; Allaf ME; Drake CG
Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
[TBL] [Abstract][Full Text] [Related]
30. Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features.
Adeniran AJ; Shuch B; Humphrey PA
Am J Surg Pathol; 2015 Dec; 39(12):e1-e18. PubMed ID: 26559379
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
32. Altered regulation of DPF3, a member of the SWI/SNF complexes, underlies the 14q24 renal cancer susceptibility locus.
Colli LM; Jessop L; Myers TA; Camp SY; Machiela MJ; Choi J; Cunha R; Onabajo O; Mills GC; Schmid V; Brodie SA; Delattre O; Mole DR; Purdue MP; Yu K; Brown KM; Chanock SJ
Am J Hum Genet; 2021 Sep; 108(9):1590-1610. PubMed ID: 34390653
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of metastatic renal cell cancer.
Fishman M; Seigne J
Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
[TBL] [Abstract][Full Text] [Related]
34. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
[TBL] [Abstract][Full Text] [Related]
35. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.
Giesen E; Jilaveanu LB; Parisi F; Kluger Y; Camp RL; Kluger HM
Oncotarget; 2014 Jul; 5(14):5209-17. PubMed ID: 24970819
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.
Wood E; Donin N; Shuch B
Urol Clin North Am; 2020 Aug; 47(3):345-358. PubMed ID: 32600536
[TBL] [Abstract][Full Text] [Related]
37. Towards individualized therapy for metastatic renal cell carcinoma.
Kotecha RR; Motzer RJ; Voss MH
Nat Rev Clin Oncol; 2019 Oct; 16(10):621-633. PubMed ID: 30992569
[TBL] [Abstract][Full Text] [Related]
38. Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
Wald G; Barnes KT; Bing MT; Kresowik TP; Tomanek-Chalkley A; Kucaba TA; Griffith TS; Brown JA; Norian LA
Urol Oncol; 2014 Jul; 32(5):589-600. PubMed ID: 24768357
[TBL] [Abstract][Full Text] [Related]
39. [Renal cell carcinoma].
Fornara P; Hoda MR
Urologe A; 2011 Sep; 50 Suppl 1():219-22. PubMed ID: 21837488
[TBL] [Abstract][Full Text] [Related]
40. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
